Trading Markets

Sign Up For Our FREE Newsletter

These 8 Biotechs Are In This Week’s Spotlight

This week, the annual meeting of the American Diabetes
Association should focus the spotlight on many companies
developing new drug treatments for diabetes (see last weekGÇÖs
biotech piece). Diabetes is a growing problem,
particularly in children, and costs this countryGÇÖs healthcare
system billions of dollars. Despite being effective, todayGÇÖs

Here’s Why I’m Watching These Six Biotech Stocks

Starting today, the 6th Annual Meeting of the American Society of Gene Therapy begins in Washington, DC, and with it begins more potential trading opportunities. This meeting, although not as popular as ASCO, is sexier than ASCO by way of its content. It brings together scientists and companies to discuss the latest cutting-edge research in gene therapy for a variety of diseases. The presentations at this meeting are pushing the envelope in applying gene therapy to the treatment of disease.

And The Early Winner Is…

The American Society of Clinical OncologyGÇÖs annual meeting began this past weekend, and so far the early winner appears to be Genentech (DNA), on many fronts.-á

Several Important Meetings Coming Soon — Here’s What I’m Looking At

Let the ASCO games begin. It looks like the ASCO floodgates have busted wide open, based on yesterdayGÇÖs biotechGÇÖs wild ride.-á The momentum all started last week with GenentechGÇÖs (DNA) release of-á positive phase III data on its new anti-angiogenesis drug.-á The instigator yesterday was ImClone (IMCLE), with a news release before the opening bell.-á The company stated it would receive a $6 million milestone payment from its European partner Merck KGaA related to the upcoming release of phase III

Why Anything Can Happen In Biotech This Week

It is only four days before the biggest meeting of
cancer specialists in the worldGǪ..and anything can
happen. Last Monday, Genentech (DNA) could not keep its
secret locked up any longer. On Monday morning, the
company fired the first preemptive shot by releasing positive
survival data on its new anti-angiogenesis drug Avastin for
the treatment

Is There More To Come From These Companies?

Will yesterdayGÇÖs wild ride for Genentech end?-áYesterday, the company initiated a preemptive release of crucial phase III data on its developing anti-angiogenesis drug Avastin a week before the start of this yearGÇÖs ASCO meeting.-áIt was a thing of beauty and caught everyone off gu

Four Big Stocks To Watch Before A Big Meeting

The 39th annual gathering of the American Society of Clinical Oncology (ASCO) is only eleven days away (May 31 to June 3) and already Wall Street speculation is brewing on which company will the toast of the meeting.-áThe ASCO meeting is the largest of the year for cancer specialists to present

Why Genentech Is In Play Today

Genentech announced this morning before the bell that a Phase III trial testing their new drug Avastin with chemotherapy improved overall survival in previously untreated patients with metastatic colorectal cancer.-áThis is significant news.-áAvastin is a monoclonal antibody aimed at a

FDA Panel Decision Is Good For These Three Stocks

After trading hours yesterday, an FDA Advisory panel unanimously approved a novel approach to treating asthma, a disease that affects millions of people worldwide. Genentech (DNA), Novartis (NOV), and the small biotech

Add These Two Biotech Stocks To Your Watchlist

Conservative numbers show erectile dysfunction to
affect over 30 million men in this country and over 130
million worldwide. The current market for drugs to treat
ED is over $1.5 billion and expects to climb to $5 billion in
three years. Obviously, this target disease is a large
market with

Lots Of Biotech Opportunities This Week…Here Are A Few

This week and next could prove to be very busy for stocks in
the biotech sector, for two reasons. As I mentioned in my
last article, on May 15 a FDA Advisory Panel will decide the
fate of the drug Xolair, a new approach to the treatment of
asthma in adolescents and adults. Three companies are
developing the drug: Tanox (TNOX), Genentech (DNA), and
Novartis (NVS). The PanelGÇÖs meeting on Thursday has all the